Edgestream Partners L.P. Decreases Stake in Halozyme Therapeutics, Inc. $HALO

Edgestream Partners L.P. lowered its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 52.2% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 51,124 shares of the biopharmaceutical company’s stock after selling 55,915 shares during the quarter. Edgestream Partners L.P.’s holdings in Halozyme Therapeutics were worth $3,304,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HALO. Norges Bank bought a new position in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $128,201,000. William Blair Investment Management LLC purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $124,031,000. Voloridge Investment Management LLC bought a new stake in Halozyme Therapeutics during the third quarter worth $77,587,000. Qube Research & Technologies Ltd bought a new stake in Halozyme Therapeutics during the second quarter worth $51,295,000. Finally, Mizuho Markets Americas LLC boosted its position in Halozyme Therapeutics by 270.8% in the fourth quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company’s stock worth $85,382,000 after purchasing an additional 926,526 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In related news, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the sale, the director owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $67.58, for a total value of $1,351,600.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at $51,886,572.40. This represents a 2.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 72,477 shares of company stock worth $5,102,643. 2.50% of the stock is owned by company insiders.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $82.54 on Friday. Halozyme Therapeutics, Inc. has a 12 month low of $58.53 and a 12 month high of $84.44. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. The business’s 50 day simple moving average is $74.52 and its 200 day simple moving average is $70.93. The company has a market cap of $9.79 billion, a price-to-earnings ratio of 29.69, a PEG ratio of 0.34 and a beta of 0.84.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The business had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. During the same period in the prior year, the company earned $1.11 earnings per share. Halozyme Therapeutics’s revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on HALO shares. UBS Group restated a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. HC Wainwright reiterated a “buy” rating and set a $95.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Weiss Ratings raised shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday. Finally, Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $81.60.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.